Reuters: Regulatory News: Pluristem says FDA lifts hold on muscle pain drug study

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Want free Kindle ebooks? Sign up to receive the best freebie Kindle ebook deals in your email every day. From our sponsors

Pluristem says FDA lifts hold on muscle pain drug study Sep 16th 2013, 11:03 Sept 16 | Mon Sep 16, 2013 7:03am EDT Sept 16 (Reuters) - Pluristem Therapeutics Inc said the U.S. Food and Drug Administration lifted its clinical hold on a mid-stage trial of the company's experimental drug for muscle pain. The company's shares rose 9 percent to $3.52 in premarket trading. The Israel-based company said the FDA allowed it to go ahead with the study, saying that Pluristem had addressed all issues related to the hold. The FDA put the study on hold in June after a patient in the study was hospitalized due to a serious allergic reaction. The company suspended trials in the United States and Europe. The drug, codenamed IND 15038, is designed to treat intermittent claudication, or pain caused by reduced blood flow to the muscles of the leg during exercise.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions